Faex Health expands AI stool analysis research to Ebola screening

Faex Health is expanding its AI-powered stool analysis research to explore whether visual markers could help pre-screen for Ebola, building on existing cholera screening and more than 100 disease research tracks. The work could add a low-cost, smartphone-based layer of outbreak surveillance, but the Ebola capabilities remain investigational and unvalidated. Why it matters: - Faex Health is targeting a major public health gap: early disease screening in places with limited diagnostic access. - If stool-image signals prove useful for Ebola risk screening, the approach could add a low-cost, non-invasive layer to outbreak surveillance. - The company’s work could be especially relevant in regions that face recurring infectious disease outbreaks and delayed detection. What happened: - Faex Health on June 18 announced a research expansion focused on identifying possible stool-based indicators of Ebola Virus Disease. - The Boulder, Colorado company said the initiative builds on its AI-powered smartphone platform for stool image analysis. - Faex Health’s platform currently pre-screens for 16 gastrointestinal conditions, including colorectal cancer, structural abnormalities, cholera, inflammatory bowel diseases and other digestive health disorders. - The new research is aimed at testing whether visual biomarkers in stool images may correlate with Ebola infection. The details: - Faex Health said the platform is designed to let a user capture a stool image on a smartphone and receive AI-generated health insights within seconds. - The company said the broader research program spans more than 100 disease categories. - Those research areas include gastrointestinal, neurological, respiratory, cardiovascular, infectious and metabolic conditions. - Faex Health said the long-term goal is to build one of the world’s most comprehensive datasets linking stool appearance with health outcomes. - The company said it is not trying to diagnose Ebola or replace laboratory testing. - The Ebola work is intended to identify statistical correlations that may support future risk assessment and outbreak detection. - Faex Health said the research is investigational and has not been clinically validated. - The company’s platform is also not intended to diagnose, treat, cure or prevent any disease. Between the lines: - The Ebola project extends Faex Health beyond digestive screening into infectious-disease surveillance, which could broaden the platform’s potential use case. - The company is positioning AI as a way to find patterns in stool imagery that human review may miss. - That framing suggests a preventive-health strategy, not a replacement for standard medical testing. - The emphasis on affordability and smartphone access points to a play for underserved and remote communities. What’s next: - Faex Health will continue research into whether stool-image features can be linked to Ebola risk. - The company is also advancing studies across more than 100 other disease categories. - Any future public health use would depend on scientific validation and clinical testing. - Faex Health said potential applications could include outbreak preparedness and population-level disease monitoring. The bottom line: - Faex Health is trying to turn stool analysis into a broader AI screening tool, with Ebola as the latest and most ambitious research target.